Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Nature reviews. Clinical oncology - 1 Dec 2017

Schram Alison M, Chang Matthew T, Jonsson Philip, Drilon Alexander

Abstract excerpt

Structural gene rearrangements resulting in gene fusions are frequent events in solid tumours. The identification of certain activating fusions can aid in the diagnosis and effective treatment of patients with tumours harbouring these alterations. Advances in the techniques used to identify fusions have enabled physicians to detect these alterations in the clinic. Targeted therapies directed at constitutively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Fusion

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 28857077
DOI: 10.1038/nrclinonc.2017.127
PMCID: PMC10452928

Genes

ALK
BRAF
FGFR1
NTRK1
PDGFB
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.PMID 28857077Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

Detecting and targetting oncogenic fusion proteins in the genomic eraSemantic proximity Read ↗

Oncogenic gene fusions in cancer: from biology to therapySemantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours.Semantic proximity Read ↗

Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.Semantic proximity Read ↗

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersSemantic proximity Read ↗

Receptor Tyrosine Kinase-Targeted Cancer TherapySemantic proximity Read ↗

Somatic alterations as the basis for resistance to targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.